Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study

S Gill¹, D Peston¹, B K Vonderhaar² and S Shousha¹

¹ Department of Histopathology, Imperial College School of Medicine, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK
² National Cancer Institute, Bethesda, Maryland, MD 20892-1402 USA

Correspondence to:
Dr Shousha s.shousha{at}ic.ac.uk

Aims—Prolactin plays an important role in the proliferation and differentiation of normal breast epithelium, and possibly in the development of breast carcinoma. The effects of prolactin are mediated by its receptor; thus, alteration in the expression of this receptor could be important in studying the biology of breast cancer. This investigation was aimed at comparing the expression of prolactin receptors in normal, benign, and malignant breast tissue.

Material/Methods—The expression of prolactin receptors was studied in paraffin wax embedded sections of 102 breast biopsies (93 female and nine male), using the monoclonal antibody B6.2, and the avidin–biotin immunoperoxidase technique. Six biopsies were normal, 34 had benign lesions, and 62 were malignant.

Results—In normal cases, prolactin receptor positivity was seen only on the luminal borders of the epithelial cells lining ducts and acini. In most benign lesions, variable degrees of luminal and cytoplasmic staining were seen. Cells showing apocrine metaplasia and florid regular ductal epithelial hyperplasia were mostly negative. In malignant cases, the staining pattern was mostly cytoplasmic and heterogeneous. Forty one of the 59 carcinomas in women showed a degree of positivity involving 10–100% of the tumour cells. A significant direct correlation was found between prolactin receptor and oestrogen receptor staining when only cases that scored more than 100/300 for the latter receptor, using the H scoring system, were considered (p = 0.0207). No correlation was found between prolactin receptors and progesterone receptors, patient's age, tumour size, tumour grade, or axillary lymph node status.

Conclusions—Prolactin receptors seem to be expressed at different cellular sites in normal, benign, and malignant breast epithelial cells. The receptor is expressed in more than two thirds of female breast carcinomas, suggesting that it may play a role in the pathogenesis of the disease. The positivity is correlated with moderate and strong staining for oestrogen receptors in tissue sections, but not with other prognostic factors.

Key Words: breast • breast carcinoma • male breast • prolactin receptors • oestrogen receptors

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Levina, V. V., Nolen, B., Su, Y., Godwin, A. K., Fishman, D., Liu, J., Mor, G., Maxwell, L. G., Herberman, R. B., Szczepanski, M. J., Szajnik, M. E., Gorelik, E., Lokshin, A. E. (2009). Biological Significance of Prolactin in Gynecologic Cancers. Cancer Res. 69: 5226-5233 [Abstract] [Full Text]  
• Galsgaard, E. D., Rasmussen, B. B., Folkesson, C. G., Rasmussen, L. M., Berchtold, M. W., Christensen, L., Panina, S. (2009). Re-evaluation of the prolactin receptor expression in human breast cancer. J Endocrinol 201: 115-128 [Abstract] [Full Text]  
• Plotnikov, A., Varghese, B., Tran, T. H., Liu, C., Rui, H., Fuchs, S. Y. (2009). Impaired Turnover of Prolactin Receptor Contributes to Transformation of Human Breast Cells. Cancer Res. 69: 3165-3172 [Abstract] [Full Text]  
• Mercier, I., Casimiro, M. C., Zhou, J., Wang, C., Plymire, C., Bryant, K. G., Daumer, K. M., Sotgia, F., Bonuccelli, G., Witkiewicz, A. K., Lin, J., Tran, T. H., Milliman, J., Frank, P. G., Jasmin, J.-F., Rui, H., Pestell, R. G., Lisanti, M. P. (2009). Genetic Ablation of Caveolin-1 Drives Estrogen-Hypersensitivity and the Development of DCIS-Like Mammary Lesions. Am. J. Pathol. 174: 1172-1190 [Abstract] [Full Text]  
• Bogorad, R. L., Courtillot, C., Mestayer, C., Bernichtein, S., Harutyunyan, L., Jomain, J.-B., Bachelot, A., Kuttenn, F., Kelly, P. A., Goffin, V., Touraine, P., the Benign Breast Diseases Study Group, (2008). Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc. Natl. Acad. Sci. USA 105: 14533-14538 [Abstract] [Full Text]  
• Plotnikov, A., Li, Y., Tran, T. H., Tang, W., Palazzo, J. P., Rui, H., Fuchs, S. Y. (2008). Oncogene-Mediated Inhibition of Glycogen Synthase Kinase 3{beta} Impairs Degradation of Prolactin Receptor. Cancer Res. 68: 1354-1361 [Abstract] [Full Text]  
• Harvey, P. W., Everett, D. J., Springall, C. J. (2008). Adverse effects of prolactin in rodents and humans: breast and prostate cancer. J Psychopharmacol 22: 20-27 [Abstract]  
• Arendt, L. M., Schuler, L. A. (2008). Prolactin Drives Estrogen Receptor-{alpha}-Dependent Ductal Expansion and Synergizes with Transforming Growth Factor-{alpha} to Induce Mammary Tumors in Males. Am. J. Pathol. 172: 194-202 [Abstract] [Full Text]  
• Neilson, L. M., Zhu, J., Xie, J., Malabarba, M. G., Sakamoto, K., Wagner, K.-U., Kirken, R. A., Rui, H. (2007). Coactivation of Janus Tyrosine Kinase (Jak)1 Positively Modulates Prolactin-Jak2 Signaling in Breast Cancer: Recruitment of ERK and Signal Transducer and Activator of Transcription (Stat)3 and Enhancement of Akt and Stat5a/b Pathways. Mol. Endocrinol. 21: 2218-2232 [Abstract] [Full Text]  
• Cheng, Y.-H., Imir, A., Suzuki, T., Fenkci, V., Yilmaz, B., Sasano, H., Bulun, S. E. (2006). SP1 and SP3 Mediate Progesterone-Dependent Induction of the 17beta Hydroxysteroid Dehydrogenase Type 2 Gene in Human Endometrium. Biol. Reprod. 75: 605-614 [Abstract] [Full Text]  
• Harvey, P W, Everett, D J, Springall, C J (2006). Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer. Hum Exp Toxicol 25: 395-404 [Abstract]  
• Utama, F E, LeBaron, M J, Neilson, L M, Sultan, A S, Parlow, A F, Wagner, K-U, Rui, H (2006). Human prolactin receptors are insensitive to mouse prolactin: implications for xenotransplant modeling of human breast cancer in mice.. J Endocrinol 188: 589-601 [Abstract] [Full Text]  
• Tworoger, S. S., Sluss, P., Hankinson, S. E. (2006). Association between Plasma Prolactin Concentrations and Risk of Breast Cancer among Predominately Premenopausal Women. Cancer Res. 66: 2476-2482 [Abstract] [Full Text]  
• Albrektsen, G., Heuch, I., Thoresen, S., Kvale, G. (2006). Clinical Stage of Breast Cancer by Parity, Age at Birth, and Time Since Birth: A Progressive Effect of Pregnancy Hormones?. Cancer Epidemiol. Biomarkers Prev. 15: 65-69 [Abstract] [Full Text]  
• Lu, J.-C., Piazza, T. M., Schuler, L. A. (2005). Proteasomes Mediate Prolactin-induced Receptor Down-regulation and Fragment Generation in Breast Cancer Cells. J. Biol. Chem. 280: 33909-33916 [Abstract] [Full Text]  
• Saglam, A, Can, B (2005). Coexistence of lactating adenoma and invasive ductal adenocarcinoma of the breast in a pregnant woman. J. Clin. Pathol. 58: 87-89 [Abstract] [Full Text]  
• Tworoger, S. S., Eliassen, A. H., Rosner, B., Sluss, P., Hankinson, S. E. (2004). Plasma Prolactin Concentrations and Risk of Postmenopausal Breast Cancer. Cancer Res. 64: 6814-6819 [Abstract] [Full Text]  
• Lacroix, M, Toillon, R-A, Leclercq, G (2004). Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer 11: 497-522 [Abstract] [Full Text]  
• Meng, J., Tsai-Morris, C.-H., Dufau, M. L. (2004). Human Prolactin Receptor Variants in Breast Cancer: Low Ratio of Short Forms to the Long-Form Human Prolactin Receptor Associated with Mammary Carcinoma. Cancer Res. 64: 5677-5682 [Abstract] [Full Text]